QIAGEN agrees to €46.50‑share all‑cash takeover by EQT‑led consortium

QIAGEN N.V. accepted an all‑cash public takeover offer of €46.50 per share from Crown NL Bidco B.V., a vehicle controlled by EQT XI and co‑investors ADIA and CPP Investments. The offer represents a 40.3% premium to the July 8, 2026 closing price and values the company at roughly €10.8 billion. The transaction requires a minimum shareholder acceptance of 50% + 1 share, shareholder and regulatory approvals, and is expected to close in mid‑2027. QIAGEN’s supervisory and managing boards unanimously recommended the offer.

The deal will take QIAGEN private, ending its public reporting and suspending its FY 2026 outlook, which removes a source of earnings guidance for investors. Shareholders will receive cash at the offer price, and the equity holders of QIAGEN will be diluted or exit depending on the acceptance threshold.

  • 1Offer price of €46.50 per share, a 40.3% premium to the July 8, 2026 closing price of €33.15.
  • 2Enterprise value of the transaction is approximately €10.8 billion (about $12.1 billion including $1.1 billion net debt).
  • 3Closing expected in mid‑2027, subject to a minimum acceptance threshold of 50% of outstanding share capital plus one share and customary regulatory clearances.
  • 4Boards of QIAGEN unanimously support and recommend acceptance of the takeover offer.
  • 5Share price rose 2.25% to $50 on the day the agreement was announced.
  • 6JPMorgan downgraded QIAGEN to Neutral, lowering its price target to $52, citing the EQT buyout.

Sources